Anti-angiogenesis drugs have been making waves as treatments for some cancers. Researchers have been developing new biomarkers to map the progress of these therapies, including those that target integrin expression. However, a new study published online yesterday in the Journal of Nuclear Medicine indicates that integrin expression imaging may not provide a mirror image of the impact of peptide therapy as it occurs.

Yet another risk factor for neurodegenerative disease has cropped up in recent studies: Worry among older women. Research conducted at the University of Gothenburg in Sweden provided a score on the scale of neuroticism for 800 women in mid-life and evaluated any potential links to Alzheimer's. Those who peaked on the anxiety scale were two times as likely to develop the disease.

A first-in-human study of (D)-18F-fluoromethyltyrosine (D-18F-FMT), a tyrosine derivative, is being evaluated for diagnostic imaging of non-small cell lung cancer (NSCLC) as well as head and neck squamous cell cancers (HNSCC). Results show that it could provide some differentiation in a space dominated by FDG, according to a study published Sept. 25 in the Journal of Nuclear Medicine.

An analysis of genetic biomarkers from Genetic Engineering & Biotechnology explains the differences between predictive and prognostic characteristics and provides a perspective on the current landscape of research and development for a number of key assays.

Myocardial perfusion imaging (MPI) with PET and F-18 flurpiridaz may reduce radiation dose while still providing comparable image quality to SPECT, the current standard, according to a study presented at the recent American Society of Nuclear Cardiology (ASNC) Annual Scientific Session held in Boston from Sept 18-21.

Lasers that can flip cells off and on and brain scanners that can be worn are just two projects receiving federal grants as a part of the $100 million BRAIN Initiative aimed to learn more about the inner-workings of the brain.

Lower amounts of a protein called progranulin in the brain have been shown to increase beta-amyloid formation and neuroinflammation. A gene therapy may be the key to reversing these markers of Alzheimer’s disease, Gladstone Institutes announced yesterday.

BioClinica, Inc., a leading provider of outsourced clinical trial services and eClinical Solutions, today announced that its Compass technology, a risk-based monitoring solution that improves overall quality in clinical trials, has won the inaugural Society for Clinical Data Management (SCDM) NextGen Technology Innovation (TIA) Award.